<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751907</url>
  </required_header>
  <id_info>
    <org_study_id>IA0138</org_study_id>
    <secondary_id>1R01AG031790</secondary_id>
    <nct_id>NCT00751907</nct_id>
  </id_info>
  <brief_title>Cerebral and Peripheral Perfusion Pilot Study</brief_title>
  <acronym>CAPP</acronym>
  <official_title>Impact of Atorvastatin on Cerebral Perfusion and Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the hypothesis that in middle-aged, asymptomatic,
      adult children of persons with Alzheimer's disease (AD), atorvastatin therapy will
      beneficially affect mechanisms thought to contribute to AD risk by improving blood flow in
      the brain, improving cerebral perfusion, increasing brain activity patterns, and improving
      blood vessel function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with cholesterol-lowering medications, specifically statins, is associated with up
      to a 73% reduction in the prevalence of AD, suggesting a potentially promising role for
      statins in the prevention of AD. In order to better understand the mechanisms through which
      statins may possibly modify blood AD risk, this study will evaluate whether administration of
      atorvastatin favorably alters blood flow in the brain (measured by magnetic resonance imaging
      (MRI)) and blood vessel function (measured by ultrasound).

      Participants will be asked to attend 3 visits over the course of the 4-month study. At the
      initial visit, participants will complete a short questionnaire about their past medical
      history and medication history. At the baseline visit, participants will be randomized in a
      1:1 ratio to receive atorvastatin 40 mg nightly vs. matching placebo. At baseline and
      follow-up visits, participants will provide an update on medical problems and medications,
      review any potential side effects, and have fasting blood tests collected for safety
      monitoring, including liver and muscle enzyme monitoring. In addition, all participants will
      have MRI and ultrasound measures collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perfusion in the posterior cingulate</measure>
    <time_frame>baseline and 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial function and pulse wave velocity</measure>
    <time_frame>Baseline and 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>40mg daily for 4 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo daily for 4 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (ages 40-65) children of parent with documented Alzheimer's disease

        Exclusion Criteria:

          -  Current use of cholesterol lowering medication

          -  History of liver disease

          -  History of adverse reaction to statin medications

          -  Elevated lab values (CK and creatinine)

          -  Use of medications that counteract with atorvastatin

          -  History of dementia

          -  Currently pregnant

          -  Use of large quantities of grapefruit juice (more than 1 quart/day)

          -  Current involvement in another investigational drug study

          -  Contraindications to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia M. Carlsson, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Newman GC, Delucia-Deranja E, Tudorica A, Hospod FE, Patlak CS. Cerebral blood volume measurements by T*2-weighted MRI and contrast infusion. Magn Reson Med. 2003 Oct;50(4):844-55.</citation>
    <PMID>14523972</PMID>
  </reference>
  <reference>
    <citation>Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J. 1995 Sep;74(3):247-53.</citation>
    <PMID>7547018</PMID>
  </reference>
  <reference>
    <citation>Wassmann S, Ribaudo N, Faul A, Laufs U, Böhm M, Nickenig G. Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels &lt;130 mg/dl. Am J Cardiol. 2004 Jan 1;93(1):84-8.</citation>
    <PMID>14697473</PMID>
  </reference>
  <reference>
    <citation>Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation. 1999 Sep 7;100(10):1050-5.</citation>
    <PMID>10477529</PMID>
  </reference>
  <reference>
    <citation>Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-58.</citation>
    <PMID>12686036</PMID>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2008</study_first_submitted>
  <study_first_submitted_qc>September 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2008</study_first_posted>
  <last_update_submitted>September 27, 2010</last_update_submitted>
  <last_update_submitted_qc>September 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Cynthia M. Carlsson, MD, MS</name_title>
    <organization>University of Wisconsin School of Medicine and Public Health</organization>
  </responsible_party>
  <keyword>Cerebral blood flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 11, 2014</submitted>
    <returned>April 16, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

